Oxbridge Re Completes Five Private Placements Of Tokenized Reinsurance Securities On Solana Blockchain, With Total Gross Proceeds Of ~$7.1M

This milestone further demonstrates SurancePlus' ability to originate, structure and distribute institutional-quality reinsurance investments through blockchain infrastructure. The securities were offered to accredited U.S. investors pursuant to Rule 506(c) of Regulation D and eligible non-U.S. investors pursuant to Regulation S under the Securities Act of 1933, as amended.

The offerings included three tokenized securities providing qualified investors with synthetic contractual exposure to designated reinsurance risk associated with HCI Group, Inc.'s (NYSE:HCI) Fortex Reinsurance SPC, Ltd. ("Fortex Re"), together with the Company's traditional tokenized reinsurance offerings. The HCI-related securities were issued as a separate investment structure on blockchain infrastructure and were not part of, nor did they affect, Fortex Re's or HCI's 2026-2027 reinsurance programs. This approach enables qualified investors to gain blockchain-enabled exposure to specified reinsurance risk without participating directly in the underlying reinsurance program

The completed offerings consisted of:

• HCI Re 2026 Series A: 100,000 tokenized interests issued at $11.10 per token, representing gross proceeds of $1.11 million. The offering targets an annual return of approximately 224% with a redemption value of $36.00 per token, assuming no underwriting losses.
• HCI Re 2026 Series B: 100,000 tokenized interests issued at $22.12 per token, representing gross proceeds of $2.212 million. The offering targets an annual return of approximately 122% with a redemption value of $49.00 per token, assuming no underwriting losses.
• HCI Re 2026 Series C: 100,000 tokenized interests issued at $30.01 per token, representing gross proceeds of $3.001 million. The offering targets an annual return of approximately 17% with a redemption value of $35.20 per token, assuming no underwriting losses.
• T42-2027: 45,335 participation shares issued at $10.00 per participation share, representing gross proceeds of approximately $453,357. The offering originally targeted an annual return 42% and have been adjusted to 32%, assuming no underwriting losses.
• T20-2027: 32,841 participation shares issued at $10.00 per participation share, representing gross proceeds of approximately $328,408. The offering originally targeted an annual return of 20% and have been adjusted to 26%, assuming no underwriting losses.
   

As a result of the completed offerings, Oxbridge expects to record approximately $13.1 million of new restricted assets on its consolidated balance sheet. The new restricted assets represent collateral supporting the Company's tokenized reinsurance securities and participation interests issued through the offerings.